Clinical Trials
27 trialsNCT06391099 2026-05-26
Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer
Ohio State University Comprehensive Cancer Center
Phase NA Suspended
NCT07405086 2026-05-22
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Phase 4 Recruiting
NCT04588246 2026-05-20
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT07576725 2026-05-08
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Phase 2 Not yet recruiting
NCT03025256 2026-05-05
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06151847 2026-04-30
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
Phase 2 Completed
NCT03017820 2026-04-13
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT05105100 2026-04-06
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
University of California, San Francisco
Completed
NCT06861647 2026-04-01
iSITE
The Wellcome Sanger Institute
Completed
NCT05929664 2026-03-24
Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery
Thomas Jefferson University
Phase 2 Recruiting
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT06349642 2026-03-12
ELEPHAS-04
Mayo Clinic
Recruiting
NCT06056895 2026-01-15
TRICK-MCC
University of Washington
Phase 2 Active not recruiting
NCT05830058 2026-01-05
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
City of Hope Medical Center
Phase 2 Recruiting
NCT06075524 2025-12-26
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Mayo Clinic
Recruiting
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT07062003 2025-12-09
Minibeam Radiation Therapy With Tungsten Slit Collimator for the Treatment of Recurrent or Metastatic Skin or Soft Tissue Tumors, MBRT1 Trial
Mayo Clinic
Phase NA Recruiting
NCT07094685 2025-11-25
SENIOR-HN
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT07155317 2025-11-12
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
Emory University
Phase 2 Recruiting
NCT06712810 2025-10-10
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
Phase 1 Recruiting
NCT05388877 2025-08-19
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
Mayo Clinic
Phase 1 Terminated
NCT05717140 2025-08-07
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
Mayo Clinic
Phase 1 Withdrawn
NCT04581382 2025-07-10
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT04967196 2024-12-10
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
Mayo Clinic
Phase 1 Terminated
NCT05740501 2023-08-04
Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer
Mayo Clinic
Completed
NCT02828345 2020-02-05
Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma
Abramson Cancer Center at Penn Medicine
Withdrawn